Abvc Biopharma (ABVC) Receivables - Net (2012 - 2024)

Abvc Biopharma (ABVC) has reported Receivables - Net for 9 consecutive years, with $1529.0 the latest figure, recorded in Q3 2024.

• For the quarter ending Q3 2024, Receivables - Net changed 0.07% year-over-year to $1529.0; the trailing twelve-month figure through Sep 2024 stood at $1529.0 (changed 0.07% YoY), and the FY2023 full-year result was $839983.0, up 10.91% from the prior year.
• Receivables - Net was little changed at $1529.0 in Q3 2024 per ABVC's latest filing, from $1530.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $839983.0 in Q4 2023 and bottomed at $1529.0 in Q3 2024.
• Historically, Receivables - Net has averaged $225176.7 across 5 years, with a median of $159712.0 in 2020.
• The sharpest annual moves came in 2021 and 2024: Receivables - Net soared 256.14% in 2021, then slumped 98.77% in 2024.
• Over 5 years, Receivables - Net stood at $159712.0 in 2020, then surged by 75.75% to $280692.0 in 2021, then soared by 169.81% to $757343.0 in 2022, then climbed by 10.91% to $839983.0 in 2023, then slumped by 99.82% to $1529.0 in 2024.
• According to Business Quant data, Receivables - Net over the past three periods registered $1529.0, $1530.0, and $1530.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.